Pulse Entdecken nav.journalClub Debatten Trends Forschende

Join discussions, follow papers, and never miss your next session.

Download on theApp Store

Start Entdecken nav.journalClub Trends

⌘+K

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia | Synapse

May 29, 2024

View Full Paper

Zodasiran, an RNAi Therapeutic Targeting ANGPTL3, for Mixed Hyperlipidemia

Key Points

Key points are not available for this paper at this time.

Abstract

Angiopoietin-like 3 (ANGPTL3) inhibits lipoprotein and endothelial lipases and hepatic uptake of triglyceride-rich lipoprotein remnants.

KI fragen

Like

Bookmark

Share

View Full Paper

KI fragen

Like

Bookmark

Share

View Full Paper

Cite This Study

Rosenson et al. (Wed,) studied this question.

synapsesocial.com/papers/68e67cc0b6db643587606c35 https://doi.org/https://doi.org/10.1056/nejmoa2404147

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

1Exome Sequencing,<i>ANGPTL3</i>Mutations, and Familial Combined Hypolipidemia2010 · 779 citations
2Cardiovascular Risk Reduction with Icosapent Ethyl for Hypertriglyceridemia2018 · 3,263 citations
3Plozasiran, an RNA Interference Agent Targeting APOC3, for Mixed Hyperlipidemia2024 · 194 citations
4ANGPTL3 Deficiency and Protection Against Coronary Artery Disease2017 · 470 citations
5Triglyceride-rich lipoproteins and their remnants: metabolic insights, role in atherosclerotic cardiovascular disease, and emerging therapeutic strategies—a consensus statement from the European Atherosclerosis Society2021 · 909 citations